Form 8-K
8-K — Gain Therapeutics, Inc.
Accession: 0001104659-26-112624
Filed: 2026-10-01
Period: 2026-10-01
CIK: 0001819411
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Other Events
Documents
8-K — tm2626750d1_8k.htm (Primary)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: tm2626750d1_8k.htm · Sequence: 1
false
0001819411
0001819411
2026-10-01
2026-10-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 1, 2026
Gain Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-40237
85-1726410
(State or Other Jurisdiction
of Incorporation)
(Commission File
Number)
(I.R.S. Employer
Identification No.)
4800 Montgomery Lane, Suite 220
Bethesda, Maryland 20814
(Address of principal executive offices, including zip code)
(301)
500-1556
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title
of Each Class:
Trading
Symbol
Name
of Each Exchange on which Registered
Common Stock, par value $0.0001 per share
GANX
The
Nasdaq Stock
Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On October 1, 2026, Gain Therapeutics, Inc. (the
“Company”) issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s
Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. The poster outlines long-term open-label extension (“OLE”)
data from the Phase 1b clinical study of rexaceract showing stabilization of Movement Disorder Society-Sponsored Revision of the Unified
Parkinson’s Disease Rating Scale (“MDS-UPDRS”) scores over 360 days (12 months) of dosing, supporting the disease-modifying
potential in Parkinson’s disease (“PD”). The data, which includes safety, tolerability, and clinical scores from the
Phase 1b nine-month study extension support continued development of rexaceract for PD.
As of August 31, 2026, 12 of the 13
evaluable patients have completed the full 12-month administration of rexaceract in the open-label extension, with one additional
participant scheduled to complete dosing in November 2026. In the 12 evaluable participants, MDS-UPDRS motor scores were stable over
the 12-month study period with rexaceract, demonstrating no clinically meaningful progression of motor symptoms on the MDS-UPDRS
Parts II and III. A clinically meaningful change in PD disease progression is generally accepted to be an increase in MDS-UPDRS Part
II and III together of approximately 6 points over a year, which also is the mean annual rate of disease progression among
individuals with early PD. Part II of the MDS-UPDRS is patient-reported motor aspects of experiences of daily living and assesses
the impact of PD on activities such as eating, dressing, walking, and other everyday functions. Part III is a clinician-assessed
motor examination, evaluating features such as tremor, rigidity, bradykinesia, speech, gait, and postural stability.
The Company expects to submit a new Phase 2 study
protocol to the U.S. Food and Drug Administration (the “FDA”) in the coming weeks, informed by insights provided by the Phase
1b study results and recent discussion with potential partners, and initiate the Phase 2 clinical trial of rexaceract in people with Parkinson’s
disease in the first quarter of 2027.
Additionally, participants with both high and
low baseline levels of the glucocerebrosidase (“GCase”) substrate glucosylsphingosine (“GluSph”) in cerebrospinal
fluid (“CSF”) show stabilization of MDS-UPDRS motor scores after 12 months and no clinically meaningful progression of motor
symptoms observed on the MDS-UPDRS Parts II and III. Though participants with high baseline levels of CSF GluSph experienced a large decrease
back towards levels observed in healthy individuals after 90 days of treatment along with a quicker observed response to rexaceract, both
groups’ MDS-UPDRS scores remained stable to baseline through 12 months of dosing.
Elevated GluSph is a hallmark of GCase dysfunction
and has been shown to increase the aggregation of alpha synuclein and to impair mitochondrial function and other intracellular processes
in neurons. A reduction in GluSph in CSF after treatment with rexaceract suggests increased GCase activity in the brain, which is expected
to impact the progression of Parkinson’s disease.
Preliminary long-term data suggest that rexaceract
is safe and generally well tolerated over 12 months of dosing. No new safety signals were observed and overall, a lower incidence of treatment-emergent
adverse events occurred in Part 2 of the study (nine-month open-label extension) compared with Part 1 (initial three-month administration).
Results from a Phase 1 study of rexaceract in
healthy volunteers demonstrated favorable safety and tolerability, plasma and central nervous system (“CNS”) exposures in
the projected therapeutic range, and target engagement with an increase in GCase activity among those receiving rexaceract at clinically
relevant doses.
Rexaceract is currently being evaluated in a Phase 1b clinical trial
for the treatment of PD with or without a GBA1 mutation. The primary endpoint of the trial, which enrolled participants across seven sites
in Australia, is to evaluate the safety and tolerability of rexaceract after three months of dosing in people with PD. The Phase 1b study
extension allowed participants to continue to be treated with rexaceract for up to a total of 12 months.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking
statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements
are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,”
“will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s
current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that
those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking
statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding:
the development of the Company’s current or future product candidates, including rexaceract; expectations regarding the timing of
patient enrollment and the completion and timing of results from the Phase 1b clinical study for rexaceract, including any extension studies;
the timing of any submissions to the FDA or other regulatory bodies and agencies; the timing of the commencement of the Phase 2 clinical
study for rexaceract; the design of the Phase 2 clinical study and whether the FDA will accept a new Phase 2 protocol; the Company’s
ability to enroll patients in its planned Phase 2 clinical study for rexaceract; whether results from preclinical studies and initial
or interim data from early clinical trials, including open-label data, will be predictive of the final results of the clinical trials
or future trials; the Company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current
or future clinical trials; the Company’s business development activities, strategic collaborations, licensing opportunities and
financing activities; the advancement, prioritization and timing of the Company’s pipeline programs, including GT-04686; and the
potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s
business in general, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings
made with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by this cautionary
notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Current
Report on Form 8-K. The Company has no obligation, and expressly disclaims any obligation, to update, revise or correct any of the forward-looking
statements, whether because of new information, future events or otherwise.
Signature
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
GAIN THERAPEUTICS, INC.
Dated: October 1, 2026
By:
/s/ Gene Mack
Gene Mack
Chief Executive Officer
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 6
v3.26.3
Cover
Oct. 01, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Oct. 01, 2026
Entity File Number
001-40237
Entity Registrant Name
Gain Therapeutics, Inc.
Entity Central Index Key
0001819411
Entity Tax Identification Number
85-1726410
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
4800 Montgomery Lane
Entity Address, Address Line Two
Suite 220
Entity Address, City or Town
Bethesda
Entity Address, State or Province
MD
Entity Address, Postal Zip Code
20814
City Area Code
301
Local Phone Number
500-1556
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
GANX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration